These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8398040)

  • 1. Antiendotoxin therapy in sepsis.
    Colletti RC; Dew RB; Goulart AE
    Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock.
    Maury E; Blanchard HS; Chauvin P; Guglielminotti J; Alzieu M; Guidet B; Offenstadt G
    J Crit Care; 2003 Jun; 18(2):115-20. PubMed ID: 12800122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiendotoxin therapies for septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
    Derkx B; Wittes J; McCloskey R
    Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy of sepsis syndrome: a comparison of the available treatments.
    Fisher CJ; Bellingan G
    Klin Wochenschr; 1991; 69 Suppl 26():162-7. PubMed ID: 1813714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
    Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
    Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiendotoxin approaches to septic shock therapy.
    Van Dervort AL; Danner RL
    Crit Care Med; 1994 Apr; 22(4):539-41. PubMed ID: 8143457
    [No Abstract]   [Full Text] [Related]  

  • 15. [Monoclonal antibodies in the treatment of sepsis and septic shock].
    Torrabadella de Reynoso P; Salgado Remigio A; Peracaula Picart R
    Med Clin (Barc); 1992 Dec; 99(20):784-92. PubMed ID: 1460952
    [No Abstract]   [Full Text] [Related]  

  • 16. Endotoxin as a therapeutic target in septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic effects of endotoxin.
    Zivot JB; Hoffman WD
    New Horiz; 1995 May; 3(2):267-75. PubMed ID: 7583168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues.
    Quezado ZM; Banks SM; Natanson C
    Trends Biotechnol; 1995 Feb; 13(2):56-63. PubMed ID: 7765996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.